cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.31109209.v2
title: Supplementary Data (Questionnaire, Participant information Sheet & Informed Consent)

description: This extended data contains an interviewer-administered research tool (knowledge questionnaire and attitude scale) to assess the knowledge and attitude of a Particularly Vulnerable Tribal Group (PVTG) in Udupi district, Karnataka, India, toward healthcare services. It also includes the Participant Information Sheet (PIS) and Informed Consent form used in this research.
DOI: 10.6084/m9.figshare.31109209.v3
title: Extended Data (Questionnaire, Participant information Sheet & Informed Consent)

description: This extended data contains an interviewer-administered research tool (knowledge questionnaire and attitude scale) to assess the knowledge and attitude of a Particularly Vulnerable Tribal Group (PVTG) in Udupi district, Karnataka, India, toward healthcare services. It also includes the Participant Information Sheet (PIS) and Informed Consent form used in this research.
DOI: 10.6084/m9.figshare.28060595
title: Proteomic analysis for busulfan-induced spermatogenesis disorder

description: Busulfan is the most commonly used drug for the treatment of chronic myelogenous leukemia and pretreatment for hematopoietic stem cell transplantation, which can damage the reproductive and immune system. However, little is known about the protein expression profiling in busulfan treated testis. This research studies the proteomics for busulfan-induced spermatogenesis disorder. The model of busulfan-induced mouse spermatogenesis disorder was subjected to label-free quantification proteomics analysis. Clustering heatmap, gene ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein interaction analyses were performed and validated by molecular experiments. The busulfan-treated mouse model showed abnormal testis morphology and reduced sperm number and testis weight. Testicular and sperm damage was most severe at 30 days after busulfan treatment. The busulfan-treated mouse testes were subjected to label-free quantification proteomics, which revealed 190 significantly downregulated proteins including lactate dehydrogenase A like 6B (LDHAL6B) and ubiquitin-specific protease 7 (USP7). In addition, the testis and spermatozoa in the epididymis progressively improved from 70 to 80 days after busulfan treatment, and that the testis weight and spermatozoa number gradually increased from 40 to 80 days after busulfan treatment. Western blotting revealed that LDHAL6B protein significantly increased at 10 days, decreased from 20 to 60 days, and then gradually elevated from 70 to 80 days after busulfan treatment. We revealed 190 significantly downregulated proteins in busulfan-treated mouse testes at 30 days and indicated that 70 days is the cut-off point of spermatogenic recovery for busulfan-treated mouse testis, increasing our understanding of this reproductive disorder model. An increased understanding of busulfan’s toxic effect will help to prevent and treat reproductive diseases.
DOI: 10.6084/m9.figshare.28060595.v1
title: Proteomic analysis for busulfan-induced spermatogenesis disorder

description: Busulfan is the most commonly used drug for the treatment of chronic myelogenous leukemia and pretreatment for hematopoietic stem cell transplantation, which can damage the reproductive and immune system. However, little is known about the protein expression profiling in busulfan treated testis. This research studies the proteomics for busulfan-induced spermatogenesis disorder. The model of busulfan-induced mouse spermatogenesis disorder was subjected to label-free quantification proteomics analysis. Clustering heatmap, gene ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein interaction analyses were performed and validated by molecular experiments. The busulfan-treated mouse model showed abnormal testis morphology and reduced sperm number and testis weight. Testicular and sperm damage was most severe at 30 days after busulfan treatment. The busulfan-treated mouse testes were subjected to label-free quantification proteomics, which revealed 190 significantly downregulated proteins including lactate dehydrogenase A like 6B (LDHAL6B) and ubiquitin-specific protease 7 (USP7). In addition, the testis and spermatozoa in the epididymis progressively improved from 70 to 80 days after busulfan treatment, and that the testis weight and spermatozoa number gradually increased from 40 to 80 days after busulfan treatment. Western blotting revealed that LDHAL6B protein significantly increased at 10 days, decreased from 20 to 60 days, and then gradually elevated from 70 to 80 days after busulfan treatment. We revealed 190 significantly downregulated proteins in busulfan-treated mouse testes at 30 days and indicated that 70 days is the cut-off point of spermatogenic recovery for busulfan-treated mouse testis, increasing our understanding of this reproductive disorder model. An increased understanding of busulfan’s toxic effect will help to prevent and treat reproductive diseases.
DOI: 10.6084/m9.figshare.28142423
title: Comparative genetic analysis of blood and semen samples in sperm donors from Hunan, China

description: At present, most genetic tests or carrier screening are performed with blood samples, and the known carrier rate of disease-causing variants is also derived from blood. For semen donors, what is really passed on to offspring is the pathogenic variant in their sperm. This study aimed to determine whether pathogenic variants identified in the sperm of young semen donors are also present in their blood, and whether matching results for blood are consistent with results for sperm. We included 40 paired sperm and blood samples from 40 qualified semen donors at the Hunan Province Human Sperm Bank of China. All samples underwent exome sequencing (ES) analysis, and the pathogenicity was assessed according to the American College of Medical Genetics (ACMG) guidelines. Scoring for sperm donation matching, which was based on gene scoring and variant scoring, was also used to assess the consistency of sperm and blood genetic test results. A total of 108 pathogenic (P)/likely pathogenic (LP) variants in 82 genes were identified. The highest carrier had 7 variants, and there was also one donor did not carry any P/LP variant. On average, each donor carried 2.7 P/LP variants. Among all the P/LP variants, missense mutation was the dominant type and most of them were located in exonic regions. Chromosome 1 harboured the largest number of variants and no pathogenic copy number variants (CNV) was identified in semen donors. The P/LP variant of all the 40 semen donors was consistent by comparing sperm and blood. Except for one case that was slightly different, the rest simulated matching results for blood were all consistent with results for sperm. It is reasonable to choose either blood or sperm for genetic screening in semen donors.
DOI: 10.6084/m9.figshare.28142423.v1
title: Comparative genetic analysis of blood and semen samples in sperm donors from Hunan, China

description: At present, most genetic tests or carrier screening are performed with blood samples, and the known carrier rate of disease-causing variants is also derived from blood. For semen donors, what is really passed on to offspring is the pathogenic variant in their sperm. This study aimed to determine whether pathogenic variants identified in the sperm of young semen donors are also present in their blood, and whether matching results for blood are consistent with results for sperm. We included 40 paired sperm and blood samples from 40 qualified semen donors at the Hunan Province Human Sperm Bank of China. All samples underwent exome sequencing (ES) analysis, and the pathogenicity was assessed according to the American College of Medical Genetics (ACMG) guidelines. Scoring for sperm donation matching, which was based on gene scoring and variant scoring, was also used to assess the consistency of sperm and blood genetic test results. A total of 108 pathogenic (P)/likely pathogenic (LP) variants in 82 genes were identified. The highest carrier had 7 variants, and there was also one donor did not carry any P/LP variant. On average, each donor carried 2.7 P/LP variants. Among all the P/LP variants, missense mutation was the dominant type and most of them were located in exonic regions. Chromosome 1 harboured the largest number of variants and no pathogenic copy number variants (CNV) was identified in semen donors. The P/LP variant of all the 40 semen donors was consistent by comparing sperm and blood. Except for one case that was slightly different, the rest simulated matching results for blood were all consistent with results for sperm. It is reasonable to choose either blood or sperm for genetic screening in semen donors.
DOI: 10.6084/m9.figshare.30207439
title: Performance of novel biomarkers for prediction of diabetic kidney disease in patients with diabetes mellitus

description: Diabetic kidney disease (DKD) is a common and serious complication in patients with diabetes mellitus (DM). This study was aimed to reveal the validity of seven emerging novel biomarkers of angiopoietin-like-4 (ANGPTL4), neutrophil gelatinase-associated lipocalin (NGAL), monocyte chemoattractant protein-1 (MCP-1), growth differentiation factor-15 (GDF15), fibroblast growth factor-23 (FGF23), n-terminal osteopontin (ntOPN) and pyruvate kinase muscle isozyme M2 (PKM2) in detecting DM patients at high risk of DKD and establish prediction models for DKD onset in DM patients. This was a cross-sectional study of 348 adult patients with Type 1 DM for at least 5 years, or Type 2 DM, followed by a prospective observational cohort of 141 adult DM patients without renal involvement at baseline and follow-up for at least 2 years. We performed logistic regression analysis to analyze the relationship between the variables and the risk of DKD occurrence, and receiver operator characteristic (ROC) analysis to assess the predictive ability of multi-biomarker panels for DKD onset. In the cross-sectional cohort, the seven urinary biomarkers were all elevated in DKD patients, of which the high levels of urinary ntOPN, GDF15, NGAL, MCP-1 and FGF23 significantly increased the risk of DKD diagnosis; the urinary MCP-1 alone performed best in DKD detection with the largest area under the ROC curve (AUC). In the prospective cohort, the high levels of urinary GDF15, MCP-1, ANGPTL4 and FGF23 significantly increased the risk of DKD development, and the model constructed based on the above four biomarkers had the largest AUC (0.873) for predicting the 2-year risk of DKD occurrence. Our study demonstrated that the four-biomarker model performed the best in predicting DKD, which could provide more accurate tools for DKD risk prediction, thereby improving the prognosis in DM patients.
DOI: 10.6084/m9.figshare.30207439.v1
title: Performance of novel biomarkers for prediction of diabetic kidney disease in patients with diabetes mellitus

description: Diabetic kidney disease (DKD) is a common and serious complication in patients with diabetes mellitus (DM). This study was aimed to reveal the validity of seven emerging novel biomarkers of angiopoietin-like-4 (ANGPTL4), neutrophil gelatinase-associated lipocalin (NGAL), monocyte chemoattractant protein-1 (MCP-1), growth differentiation factor-15 (GDF15), fibroblast growth factor-23 (FGF23), n-terminal osteopontin (ntOPN) and pyruvate kinase muscle isozyme M2 (PKM2) in detecting DM patients at high risk of DKD and establish prediction models for DKD onset in DM patients. This was a cross-sectional study of 348 adult patients with Type 1 DM for at least 5 years, or Type 2 DM, followed by a prospective observational cohort of 141 adult DM patients without renal involvement at baseline and follow-up for at least 2 years. We performed logistic regression analysis to analyze the relationship between the variables and the risk of DKD occurrence, and receiver operator characteristic (ROC) analysis to assess the predictive ability of multi-biomarker panels for DKD onset. In the cross-sectional cohort, the seven urinary biomarkers were all elevated in DKD patients, of which the high levels of urinary ntOPN, GDF15, NGAL, MCP-1 and FGF23 significantly increased the risk of DKD diagnosis; the urinary MCP-1 alone performed best in DKD detection with the largest area under the ROC curve (AUC). In the prospective cohort, the high levels of urinary GDF15, MCP-1, ANGPTL4 and FGF23 significantly increased the risk of DKD development, and the model constructed based on the above four biomarkers had the largest AUC (0.873) for predicting the 2-year risk of DKD occurrence. Our study demonstrated that the four-biomarker model performed the best in predicting DKD, which could provide more accurate tools for DKD risk prediction, thereby improving the prognosis in DM patients.
DOI: 10.6084/m9.figshare.30610393
title: Association of CXCL16 in aseptic loosening following total hip arthroplasty and its effect on bone metabolism: a case-control study

description: Aseptic loosening commonly leads to surgical failure and revision arthroplasty after total hip arthroplasty (THA). C-X-C motif chemokine ligand 16 (CXCL16), a chemokine involved in various inflammatory and immune responses, has been implicated in bone metabolism. This single-institution study investigated the association between CXCL16 and aseptic loosening following THA. We compared 100 patients who underwent revision THA due to aseptic loosening (experimental group) to 100 patients who underwent primary THA for femoral neck fracture or congenital hip dysplasia (control group). Immunohistochemistry and RT-PCR were used to assess CXCL16 expression at the protein and mRNA levels. Double immunofluorescence staining determined the RANKL/OPG ratio in periarticular synovial tissues. Statistical analysis included a chi-square test for CXCL16 protein expression differences and Pearson correlation for the relationship between CXCL16 mRNA expression and RANKL/OPG. Proteomics analysis revealed significantly higher CXCL16 expression in the experimental group compared to the control group (<i>p</i> &lt; .01). Immunohistochemistry confirmed that 90% of samples in the experimental group showed positive CXCL16 staining compared to 7% in the control group (<i>p</i> &lt; .01). RT-PCR demonstrated a 3.4-fold higher CXCL16 mRNA expression in the experimental group relative to controls (<i>p</i> &lt; .01). TRAP staining identified that 72% of CXCL16+ multinucleated giant cells in the experimental group were macrophages. Immunohistochemical staining showed that 73% of CXCL16+ macrophages were M2 type, and 27% were M1 type. Dual-immunofluorescence staining indicated an increase in the RANKL/OPG ratio in the experimental group, with a positive linear correlation between CXCL16 mRNA expression and the RANKL/OPG ratio (<i>r</i> = .919, <i>p</i> &lt; .01). Our findings reveal a significant association between elevated CXCL16 expression and an increased RANKL/OPG ratio in periprosthetic synovial tissues, suggesting a role for CXCL16 in promoting osteoclast differentiation and activity. These findings offer preliminary insights into CXCL16 as a biomarker and a potential therapeutic target for managing bone resorption in aseptic loosening.
DOI: 10.6084/m9.figshare.30610393.v1
title: Association of CXCL16 in aseptic loosening following total hip arthroplasty and its effect on bone metabolism: a case-control study

description: Aseptic loosening commonly leads to surgical failure and revision arthroplasty after total hip arthroplasty (THA). C-X-C motif chemokine ligand 16 (CXCL16), a chemokine involved in various inflammatory and immune responses, has been implicated in bone metabolism. This single-institution study investigated the association between CXCL16 and aseptic loosening following THA. We compared 100 patients who underwent revision THA due to aseptic loosening (experimental group) to 100 patients who underwent primary THA for femoral neck fracture or congenital hip dysplasia (control group). Immunohistochemistry and RT-PCR were used to assess CXCL16 expression at the protein and mRNA levels. Double immunofluorescence staining determined the RANKL/OPG ratio in periarticular synovial tissues. Statistical analysis included a chi-square test for CXCL16 protein expression differences and Pearson correlation for the relationship between CXCL16 mRNA expression and RANKL/OPG. Proteomics analysis revealed significantly higher CXCL16 expression in the experimental group compared to the control group (<i>p</i> &lt; .01). Immunohistochemistry confirmed that 90% of samples in the experimental group showed positive CXCL16 staining compared to 7% in the control group (<i>p</i> &lt; .01). RT-PCR demonstrated a 3.4-fold higher CXCL16 mRNA expression in the experimental group relative to controls (<i>p</i> &lt; .01). TRAP staining identified that 72% of CXCL16+ multinucleated giant cells in the experimental group were macrophages. Immunohistochemical staining showed that 73% of CXCL16+ macrophages were M2 type, and 27% were M1 type. Dual-immunofluorescence staining indicated an increase in the RANKL/OPG ratio in the experimental group, with a positive linear correlation between CXCL16 mRNA expression and the RANKL/OPG ratio (<i>r</i> = .919, <i>p</i> &lt; .01). Our findings reveal a significant association between elevated CXCL16 expression and an increased RANKL/OPG ratio in periprosthetic synovial tissues, suggesting a role for CXCL16 in promoting osteoclast differentiation and activity. These findings offer preliminary insights into CXCL16 as a biomarker and a potential therapeutic target for managing bone resorption in aseptic loosening.
DOI: 10.6084/m9.figshare.29648020
title: Carcinoembryonic antigen as a predictor of treatment outcomes in cancer patients receiving immune checkpoint inhibitors

description: Carcinoembryonic antigen (CEA) is a widely used tumor marker and is associated with traditional therapeutic efficacy. Our study aims to assess the predictive significance of baseline carcinoembryonic antigen (CEA) levels and CEA level changes on the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. A systemic literature search was conducted in three digital repositories—Embase, PubMed, and the Cochrane Library—to obtain studies linking CEA with clinical results in cancer patients receiving ICIs from the year of inception of each database until 20 August 2024. Studies were included if they involved cancer patients treated with ICIs, assessed the prognostic significance of baseline CEA levels or CEA level changes, and reported at least one outcome metric, including overall survival (OS), progression-free survival (PFS), disease control rate (DCR), pathological complete response (pCR), or objective response rate (ORR). Duplicate studies were identified and removed using Covidence software following Cochrane collaboration guidelines. The Newcastle-Ottawa Scale was applied to evaluate study quality. Pooled hazard ratios (HRs) for OS and PFS, as well as odds ratios (ORs) for DCR, pCR, and ORR, were calculated with 95% confidence intervals (CIs). The analysis included 27 studies, comprising a total cohort of 3662 patients. The findings revealed that cancer patients receiving ICIs with lower CEA levels had significantly improved OS (HR: 1.84, <i>p</i> &lt; 0.001) and PFS (HR: 1.64, <i>p</i> &lt; 0.001), along with higher DCR (OR: 1.81, <i>p</i> = 0.001), ORR (OR: 0.53, <i>p</i> = 0.001), and pCR (OR: 0.58, <i>p</i> &lt; 0.001) compared to those with elevated CEA levels. Additionally, a reduction in CEA levels during immunotherapy was significantly associated with prolonged OS (HR: 0.507, <i>p</i> &lt; 0.001) and PFS (HR: 0.501, <i>p</i> &lt; 0.001), as well as increased ORR (OR: 2.39, <i>p</i> = 0.005) and DCR (OR: 2.94, <i>p</i> &lt; 0.001). The results advocate for integrating CEA level assessments into the prognostic analysis for cancer patients.
DOI: 10.6084/m9.figshare.29648020.v1
title: Carcinoembryonic antigen as a predictor of treatment outcomes in cancer patients receiving immune checkpoint inhibitors

description: Carcinoembryonic antigen (CEA) is a widely used tumor marker and is associated with traditional therapeutic efficacy. Our study aims to assess the predictive significance of baseline carcinoembryonic antigen (CEA) levels and CEA level changes on the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. A systemic literature search was conducted in three digital repositories—Embase, PubMed, and the Cochrane Library—to obtain studies linking CEA with clinical results in cancer patients receiving ICIs from the year of inception of each database until 20 August 2024. Studies were included if they involved cancer patients treated with ICIs, assessed the prognostic significance of baseline CEA levels or CEA level changes, and reported at least one outcome metric, including overall survival (OS), progression-free survival (PFS), disease control rate (DCR), pathological complete response (pCR), or objective response rate (ORR). Duplicate studies were identified and removed using Covidence software following Cochrane collaboration guidelines. The Newcastle-Ottawa Scale was applied to evaluate study quality. Pooled hazard ratios (HRs) for OS and PFS, as well as odds ratios (ORs) for DCR, pCR, and ORR, were calculated with 95% confidence intervals (CIs). The analysis included 27 studies, comprising a total cohort of 3662 patients. The findings revealed that cancer patients receiving ICIs with lower CEA levels had significantly improved OS (HR: 1.84, <i>p</i> &lt; 0.001) and PFS (HR: 1.64, <i>p</i> &lt; 0.001), along with higher DCR (OR: 1.81, <i>p</i> = 0.001), ORR (OR: 0.53, <i>p</i> = 0.001), and pCR (OR: 0.58, <i>p</i> &lt; 0.001) compared to those with elevated CEA levels. Additionally, a reduction in CEA levels during immunotherapy was significantly associated with prolonged OS (HR: 0.507, <i>p</i> &lt; 0.001) and PFS (HR: 0.501, <i>p</i> &lt; 0.001), as well as increased ORR (OR: 2.39, <i>p</i> = 0.005) and DCR (OR: 2.94, <i>p</i> &lt; 0.001). The results advocate for integrating CEA level assessments into the prognostic analysis for cancer patients.